VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit – Marketwired (press release)
|
VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit
Marketwired (press release) VBI-1901 is a novel immunotherapy developed using VBI's eVLP technology to target CMV-positive (CMV+) tumors, including glioblastoma multiforme (GBM), the company's lead immuno-oncology program. Dr. Anderson will present data in animal models … |
